A randomized , double blind, multicenter, phase III study of Everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin
Advanced Neuroendocrine tumors of GI or lung origin
Neurodendocrine tumors, Everolimus, GI, Lung
Safety and/or Efficacy Study
Eligibility and IRB
Adult patients with histologically confirmed advanced low and intermediate grade nonfunctional NET of GI or lung origin with measurable disease at baseline whose disease progressed within the past six months
Patients with a history of carcinoid syndrome and/or active symptoms of carcinoid at the time of screening are excluded. Poorly differentiated/high grade tumors are excluded.